Continuous Versus Fixed-Duration Treatment for Frontline Chronic Lymphocytic Leukemia

In this episode, contributing editor Dr. Lauren Pommert speaks with Dr. Sarah Tasian, pediatric oncologist at the Children’s Hospital of Philadelphia. They discuss the new International Consensus Recommendations for Pediatric Acute Myeloid Leukemia. 

In this episode contributing editor Dr. Ajai Chari speaks with Dr. Roberto Mina, assistant professor of Hematology at Emory University about two recent myeloma studies published in the New England Journal of Medicine. 

In this episode contributing editor, Lori Muffly, MD, MS, speaks with a celebrated leader in the field of bone marrow transplantation, Mary Horowitz, MD, MS, of the Medical College of Wisconsin. 

In this episode, Contributing Editor, Brian Hill, MD, speaks with Juan Alderuccio, MD, of the University of Miami Cancer Center, about a landmark study that supports refined treatment approaches for secondary central nervous system large B-cell lymphoma.

In this episode, Contributing Editor Meera Sridharan, MD, PhD, speaks with Hiroyuki Matsui, MD, PhD, assistant professor in the department of hematology at Kyoto University Hospital in Japan. Their conversation focuses on the role of narsoplimab in treating a potentially fatal hematologic disorder.

In this episode, Contributing Editor Tycel Phillips, MD, speaks with Arnon Kater, MD, of Amsterdam University Medical Center in the Netherlands. Their conversation focuses on the potential role of bispecific antibodies in managing patients with Richter transformation. 

In this episode, Michael Scott, MD, from the University of Toronto, St. Michael’s Hospital, speaks with Samuel Wilson, MD, of the University of North Carolina at Chapel Hill. Their conversation focuses on recent trials examining secondary prevention of venous thromboembolism in higher-risk patients. 

In this episode, Contributing Editor Brian Hill, MD, PhD, speaks with Meghan Thompson, MD, of Memorial Sloan Kettering Cancer Center in New York. Their conversation focuses on Continuous Versus Fixed-Duration Treatment for Frontline Chronic Lymphocytic Leukemia.

In this episode, Contributing Editor Charlotte Brierley, MD, PhD, speaks with Jacqueline Garcia, MD, assistant professor at the Dana Farber Cancer Institute and Harvard Medical School and an expert in myeloid neoplasms. Their discussion focuses on the VERONA trial and its impact on the myelodysplastic syndromes community. 

In this episode Contributing Editor Brian Hill, MD, talks with Brian Koffman, MDCM, retired family doctor and chronic lymphocytic leukemia patient. Dr. Koffman is co-founder and chief medical officer of the CLL Society. They discuss Dr. Koffman’s journey as both a physician and a patient.